AR120578A1 - DERIVADOS DE BENCILAMIDA COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 (TGFbRI) / ALK5 - Google Patents
DERIVADOS DE BENCILAMIDA COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 (TGFbRI) / ALK5Info
- Publication number
- AR120578A1 AR120578A1 ARP200103298A ARP200103298A AR120578A1 AR 120578 A1 AR120578 A1 AR 120578A1 AR P200103298 A ARP200103298 A AR P200103298A AR P200103298 A ARP200103298 A AR P200103298A AR 120578 A1 AR120578 A1 AR 120578A1
- Authority
- AR
- Argentina
- Prior art keywords
- tgfbri
- growth factor
- halogen atoms
- transforming growth
- optionally substituted
- Prior art date
Links
- 102000009618 Transforming Growth Factors Human genes 0.000 title abstract 2
- 108010009583 Transforming Growth Factors Proteins 0.000 title abstract 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical class NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 title 1
- 108091006082 receptor inhibitors Proteins 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000017066 negative regulation of growth Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19383057 | 2019-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120578A1 true AR120578A1 (es) | 2022-02-23 |
Family
ID=68808255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200103298A AR120578A1 (es) | 2019-11-28 | 2020-11-27 | DERIVADOS DE BENCILAMIDA COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 (TGFbRI) / ALK5 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12297186B2 (enExample) |
| EP (1) | EP4065572A1 (enExample) |
| JP (2) | JP7808032B2 (enExample) |
| KR (1) | KR20220107180A (enExample) |
| CN (1) | CN114787145B (enExample) |
| AR (1) | AR120578A1 (enExample) |
| AU (1) | AU2020394531A1 (enExample) |
| BR (1) | BR112022010251A2 (enExample) |
| CA (1) | CA3160963A1 (enExample) |
| ES (1) | ES3029608T1 (enExample) |
| IL (1) | IL293388B2 (enExample) |
| MX (1) | MX2022005843A (enExample) |
| PH (1) | PH12022551177A1 (enExample) |
| SA (1) | SA522432749B1 (enExample) |
| WO (1) | WO2021105317A1 (enExample) |
| ZA (1) | ZA202205149B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3978487A1 (en) | 2020-09-30 | 2022-04-06 | Origo Biopharma, S.L. | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
| WO2025176835A1 (en) | 2024-02-22 | 2025-08-28 | Agomab Spain S.L.U. | Crystalline phase forms of a benzylamide derivative |
| WO2026082960A1 (en) | 2024-10-18 | 2026-04-23 | Agomab Therapeutics Nv | 1,5-naphtyridine and quinoline based inhibitors of alk5 |
| WO2026082968A1 (en) | 2024-10-18 | 2026-04-23 | Agomab Therapeutics Nv | Novel compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3621540A1 (de) | 1986-06-27 | 1988-01-07 | Basf Ag | Chinolinderivate, verfahren zu ihrer herstellung, diese enthaltende mikrobizide und ihre verwendung zur bekaempfung von bakterien und pilzen |
| US20040087623A1 (en) | 2001-02-02 | 2004-05-06 | Gellibert Francoise Jeanne | Pyrazole derivatives against tgf overexpression |
| OA12929A (en) | 2002-09-18 | 2006-10-13 | Pfizer Prod Inc | Pyrazole derivatives as transforming growth (TGF) inhibitors. |
| AU2003268155A1 (en) | 2002-09-19 | 2004-04-08 | Eli Lilly And Company | Methods of inhibiting tgf beta with substituted pyrazoles |
| CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| WO2009123316A1 (ja) | 2008-04-04 | 2009-10-08 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| BR112012018358A2 (pt) | 2009-12-21 | 2016-08-09 | Bayer Cropscience Ag | tienilpiri(mi)dinilazol e seu uso para controlar fungos fitopatogênicos |
| AU2012281281B2 (en) * | 2011-07-13 | 2017-06-01 | Tiumbio Co., Ltd | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| US11021468B2 (en) * | 2015-04-01 | 2021-06-01 | Rigel Pharmaceuticals, Inc. | TGF-ß inhibitors |
| US11040976B2 (en) | 2015-04-24 | 2021-06-22 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof |
| KR102434226B1 (ko) * | 2016-06-30 | 2022-08-19 | 한미약품 주식회사 | Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도 |
| CA3091533A1 (en) | 2018-03-02 | 2019-09-06 | Universite De Lausanne | Pyrazole derivatives as inhibitors of the wnt signalling pathway |
| US11945803B2 (en) | 2018-08-07 | 2024-04-02 | Tosk, Inc. | Modulators of RAS GTPase |
| CN110433164A (zh) | 2019-08-15 | 2019-11-12 | 南开大学 | TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用 |
| EP3978487A1 (en) | 2020-09-30 | 2022-04-06 | Origo Biopharma, S.L. | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
-
2020
- 2020-11-27 PH PH1/2022/551177A patent/PH12022551177A1/en unknown
- 2020-11-27 CN CN202080080848.3A patent/CN114787145B/zh active Active
- 2020-11-27 WO PCT/EP2020/083566 patent/WO2021105317A1/en not_active Ceased
- 2020-11-27 ES ES20811359T patent/ES3029608T1/es active Pending
- 2020-11-27 JP JP2022531434A patent/JP7808032B2/ja active Active
- 2020-11-27 AU AU2020394531A patent/AU2020394531A1/en active Pending
- 2020-11-27 IL IL293388A patent/IL293388B2/en unknown
- 2020-11-27 EP EP20811359.7A patent/EP4065572A1/en active Pending
- 2020-11-27 US US17/780,099 patent/US12297186B2/en active Active
- 2020-11-27 KR KR1020227017493A patent/KR20220107180A/ko active Pending
- 2020-11-27 CA CA3160963A patent/CA3160963A1/en active Pending
- 2020-11-27 BR BR112022010251A patent/BR112022010251A2/pt unknown
- 2020-11-27 MX MX2022005843A patent/MX2022005843A/es unknown
- 2020-11-27 AR ARP200103298A patent/AR120578A1/es unknown
-
2022
- 2022-05-10 ZA ZA2022/05149A patent/ZA202205149B/en unknown
- 2022-05-26 SA SA522432749A patent/SA522432749B1/ar unknown
-
2025
- 2025-05-06 US US19/200,279 patent/US20250333395A1/en active Pending
- 2025-07-10 JP JP2025116497A patent/JP2025163046A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12297186B2 (en) | 2025-05-13 |
| SA522432749B1 (ar) | 2025-05-12 |
| IL293388B2 (en) | 2026-04-01 |
| WO2021105317A1 (en) | 2021-06-03 |
| CA3160963A1 (en) | 2021-06-03 |
| KR20220107180A (ko) | 2022-08-02 |
| AU2020394531A1 (en) | 2022-06-09 |
| IL293388B1 (en) | 2025-12-01 |
| MX2022005843A (es) | 2022-07-19 |
| ZA202205149B (en) | 2025-06-25 |
| CN114787145A (zh) | 2022-07-22 |
| US20230025933A1 (en) | 2023-01-26 |
| PH12022551177A1 (en) | 2024-02-05 |
| BR112022010251A2 (pt) | 2022-09-06 |
| JP2023504795A (ja) | 2023-02-07 |
| EP4065572A1 (en) | 2022-10-05 |
| JP7808032B2 (ja) | 2026-01-28 |
| US20250333395A1 (en) | 2025-10-30 |
| IL293388A (en) | 2022-07-01 |
| ES3029608T1 (en) | 2025-06-24 |
| JP2025163046A (ja) | 2025-10-28 |
| CN114787145B (zh) | 2024-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017009891A2 (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
| CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| AR106605A1 (es) | Oxadiazoles sustituidos para combatir hongos fitopatógenos | |
| MX383051B (es) | Compuestos que inhiben eif4a y métodos relacionados a los mismos. | |
| MX381041B (es) | Compuesto cíclico tipo cumarina como inhibidor de mek y su uso. | |
| UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR071055A1 (es) | Compuestos espiro, composiciones farmaceuticas y medicamentos que los comprenden, agente promotor de la secrecion de insulina y usos para la preparacion de medicamentos y composiciones farmaceuticas | |
| MX380928B (es) | Inhibidores de kras g12c. | |
| EA201591890A1 (ru) | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| MX373711B (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| ECSP17021897A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
| AR098522A1 (es) | Compuesto de triazolo-piridina | |
| AR102851A1 (es) | Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática | |
| CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
| CY1124527T1 (el) | Σκευασματα αναστολεα pi3k/mtor για ενδοφλεβια χορηγηση | |
| MX2024003399A (es) | Derivados de piridazinil-amino como inhibidores del receptor del factor de crecimiento transformante beta tipo i (alk5). | |
| AR103629A1 (es) | Compuestos con actividad antitumoral | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| CY1123185T1 (el) | Παραγωγα ινδολιου | |
| AR104539A1 (es) | Compuestos cíclicos | |
| AR112463A1 (es) | Derivados de propanamina para tratar el dolor y estados relacionados con dolor | |
| AR109688A1 (es) | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos |